LAE102 is our internally discovered monoclonal antibody against ActRIIA, the first ActRIIA-specific antibody in clinical stage development for the treatment of obesity globally.

Blocking Activin-ActRII pathway could promote muscle regeneration and reduce fat mass, positioning LAE102 as a promising drug candidate for muscle-preserving weight control. Topline results from Phase I studies of LAE102 (ActRIIA monoclonal antibody) in the U.S. and China demonstrated encouraging, dose-dependent trends in lean mass increase and fat mass reduction, as well as a well-tolerated safety profile.

Laekna team has accumulated tremendous experience and extensive knowhow in this specific field and is developing, in addition to LAE102, more drug candidates to maximize the value of targeting ActRII receptors. LAE103 is an ActRIIB-selective antibody now in Phase I SAD Study in Australia. LAE123 is an ActRIIA/IIB dual antagonistic monoclonal antibody. Both are our internally discovered antibodies for muscle and other disease indications.